outbreak
becom
global
pandem
respons
confirm
case
death
worldwid
studi
examin
immunogen
choexpress
recombin
fusion
protein
mice
rabbit
monkey
potenti
candid
vaccin
demonstr
fusion
protein
extrem
immunogen
evidenc
strong
antibodi
titer
observ
day
strong
viru
neutral
activ
observ
day
rabbit
immun
fusion
protein
use
pseudoviru
neutral
assay
importantli
less
day
three
inject
fusion
protein
two
monkey
develop
higher
viru
neutral
titer
recov
patient
live
infect
assay
data
strongli
suggest
choexpress
recombin
protein
could
strong
candid
vaccin
develop
first
identifi
wuhan
china
end
four
short
month
viru
caus
global
pandem
confirm
case
death
worldwid
novel
coronaviru
effect
treatment
drug
current
avail
vaccin
dire
need
develop
sever
broad
approach
develop
vaccin
emerg
includ
dna
vaccin
rna
vaccin
viral
vector
vaccin
recombin
subunit
vaccin
dead
viral
prepar
among
rna
vaccin
moderna
first
reach
human
trial
earli
march
us
follow
cansino
adenovir
vector
vaccin
began
human
trial
china
later
month
consid
spike
protein
receptorbind
protein
mediat
viralcel
fusion
initi
infect
event
favor
select
primari
target
vaccin
design
spike
protein
total
amino
acid
divid
two
major
domain
accord
structur
function
first
half
protein
contain
rbd
sequenc
locat
nterminu
spike
protein
second
half
serv
trimer
structur
support
receptor
bind
site
fusion
bundl
protrud
host
cell
membran
trigger
come
contact
ace
ii
due
fact
neutral
epitop
locat
within
region
protein
contain
region
rbd
even
trimer
approach
consid
candid
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
vaccin
develop
studi
clone
protein
genbank
vaccin
candid
eukaryot
express
construct
stabli
express
cell
purifi
protein
formul
adjuv
immun
mice
rabbit
monkey
besid
elicit
high
level
antibodi
higher
neutral
activ
also
found
antisera
monkey
compar
sera
convalesc
human
patient
result
indic
protein
effect
induc
humor
immun
respons
variou
anim
elicit
high
level
neutral
antibodi
monkey
saponin
base
microemuls
advaccin
biopharma
china
freund
complet
adjuv
cfa
purchas
sigma
usa
femal
balbc
mice
obtain
vital
river
co
china
new
zealand
white
rabbit
purchas
host
longan
co
china
cynomolgu
monkey
host
xieerxin
biotech
china
peroxidas
conjug
secondari
antibodi
sourc
jackson
immunoresearch
usa
choexpress
fusion
produc
purifi
zheng
biotech
china
immun
weeksold
femal
balbc
mice
weeksold
femal
nzw
rabbit
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
year
old
cynomolgu
monkey
immun
choexpress
fusion
formul
adjuv
accord
manufactur
instruct
blood
sampl
collect
differ
time
point
measur
antibodi
level
neutral
titer
assay
carri
describ
zhao
rq
et
al
briefli
well
plate
coat
protein
block
bsapb
serial
dilut
sera
first
dilut
normal
sera
serum
sampl
inactiv
serial
dilut
cell
cultur
medium
twofold
step
dilut
serum
mix
suspens
plate
ratio
follow
hour
incub
incub
vero
cell
ad
serumviru
mixtur
plate
incub
day
incub
cytopath
effect
cpe
well
record
microscop
neutral
titer
calcul
dilut
number
protect
condit
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
protein
fuse
fc
fragment
human
eas
purif
express
stabl
cho
cell
line
fusion
protein
purifi
cultur
supernat
use
proteina
column
shown
puriti
protein
evalu
run
sdspage
gel
reduc
nonreduc
condit
band
kd
detect
monom
dimer
appear
singl
band
well
kd
molecul
marker
suggest
protein
heavili
glycosyl
origin
purpos
studi
gener
posit
control
antibodi
develop
vaccin
serolog
assay
strong
adjuv
freund
complet
adjuv
cfa
saponinbas
microemuls
use
immun
anim
four
old
femal
balbc
mice
first
immun
recombin
protein
immers
cfa
boost
protein
multipl
time
short
interv
tail
bleed
collect
differ
time
antibodi
titer
examin
elisa
purifi
day
immun
mice
show
syndrom
fever
much
earlier
usual
suggest
fusion
protein
super
immunogen
tail
bleed
collect
right
way
antibodi
igg
titer
examin
use
hrpconjug
goat
antimous
igg
fcspecif
secondari
antibodi
shown
fig
day
one
boost
day
mous
igg
titer
reach
day
sacrif
spleenocyt
use
gener
mous
monoclon
antibodi
remain
three
mice
also
develop
igg
titer
higher
day
day
volum
mous
sera
littl
meet
need
posit
control
two
rabbit
immun
fusion
protein
later
day
day
multipl
inject
similar
mice
immun
rabbit
alreadi
develop
high
titer
higher
protein
see
fig
addit
one
femal
one
male
monkey
immun
protein
use
day
sera
collect
differ
day
evalu
elisa
hrpconjug
goat
antihuman
igg
hl
secondari
antibodi
react
igm
use
detect
total
antibodi
hrplabel
antihuman
igg
fc
hrpconjug
mous
antihuman
use
detect
igg
igm
respect
fig
day
total
antibodi
detect
femal
monkey
day
two
boost
good
titer
total
antibodi
observ
monkey
howev
day
signific
drop
total
antibodi
titer
femal
monkey
one
boost
given
day
total
antibodi
titer
monkey
increas
greatli
use
isotypespecif
secondari
antibodi
reexamin
sera
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
shown
fig
igg
antibodi
seen
femal
monkey
day
day
strong
igg
titer
detect
monkey
igm
level
undetect
interestingli
one
boost
day
big
increas
igg
titer
also
signific
increas
igm
titer
observ
igm
igg
detect
patient
mayb
indic
either
reinfect
reemerg
infect
human
cell
also
examin
level
igg
igm
antibodi
plasma
sampl
collect
differ
day
post
onset
diseas
recov
patient
shown
fig
igg
antibodi
detect
day
onset
titer
increas
day
reduc
significantli
day
igm
detect
viru
neutral
activ
immun
sera
examin
use
either
pseudoviru
live
neutral
activ
sera
immun
rabbit
examin
use
pseudoviru
briefli
heatinactiv
serum
sampl
serial
dilut
incub
pseudovirus
h
mixtur
use
infect
cell
three
day
later
luciferas
activ
infect
cell
measur
neutral
titer
calcul
probit
analysi
use
spss
softwar
shown
fig
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
neutral
titer
obtain
rabbit
receiv
three
consecut
immun
also
compar
neutral
titer
sera
immun
data
clearli
suggest
choexpress
full
length
fusion
protein
solicit
strong
neutral
activ
reason
short
time
could
good
candid
vaccin
develop
spike
protein
total
amino
acid
two
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
major
domain
accord
structur
function
first
half
protein
contain
rbd
sequenc
locat
nterminu
spike
protein
second
half
serv
trimer
structur
support
receptor
bind
structur
place
due
rbd
locat
within
region
gener
fusion
protein
candid
vaccin
develop
sinc
protein
predict
least
nlink
glycosyl
site
chose
mammalian
cell
express
system
ensur
right
glycosyl
also
one
popular
cell
line
use
make
human
antibodi
drug
shringrix
vaccin
base
recombin
ge
protein
varicellazost
viru
launch
gsk
prevent
treatment
shingl
great
success
primari
vaccin
schedul
consist
two
dose
two
month
apart
assum
vaccin
schedul
stabl
express
level
fusion
protein
l
cho
cell
bioreactor
easili
produc
million
dose
recombin
vaccin
everi
two
week
mani
antibodi
drug
product
plant
world
may
feasibl
way
make
enough
vaccin
entir
world
within
one
year
mani
therapeut
biolog
drug
tnf
receptorfc
fusion
protein
enbrel
use
treatment
amd
human
diseas
without
known
sideeffect
caus
fc
part
drug
dimer
fusion
protein
via
disulfid
bond
form
within
hing
region
fc
may
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
help
mimic
conform
oligomer
protein
vivo
importantli
human
fc
domain
fuse
c
termin
protein
greatli
facilit
purif
recombin
protein
follow
standard
antibodi
drug
manufactur
procedur
use
purifi
recombin
fusion
protein
immunogen
demonstr
good
immunogen
mice
rabbit
nonhuman
primat
also
elicit
strong
neutral
activ
infect
vitro
studi
potenti
antibodydepend
enhanc
ade
current
underway
use
protein
challeng
mice
immun
fusion
protein
exhibit
strong
titer
moment
observ
abnorm
mice
studi
establish
cell
line
stabli
express
protein
human
igg
fc
fuse
c
termin
purifi
recombin
fusion
protein
formul
saponinbas
microemuls
adjuv
use
immun
mice
rabbit
monkey
besid
high
level
antibodi
elicit
higher
neutral
activ
live
antisera
monkey
develop
within
day
compar
sera
recov
patient
result
demonstr
fusion
fig
antibodi
level
immun
mice
rabbit
serum
sampl
collect
differ
mice
differ
day
evalu
coat
plate
elisa
use
mous
iggspecif
secondari
antibodi
vertic
coordin
igg
titer
b
serum
sampl
collect
differ
rabbit
differ
day
evalu
coat
plate
elisa
use
rabbit
iggspecif
secondari
antibodi
horizont
coordin
dilut
vertic
coordin
absorb
valu
fig
antibodi
level
immun
monkey
titer
total
antibodi
monkey
serum
sera
evalu
elisa
use
hrpconjug
goatantihuman
igg
hl
secondari
antibodi
horizont
coordin
time
vertic
coordin
titer
antibodi
sera
b
level
igg
igm
monkey
sera
sera
examin
either
hrpconjug
goat
anti
human
igg
fcspecif
secondari
antibodi
hrpconjug
mous
monoclon
human
igm
horizont
coordin
time
vertic
coordin
absorb
valu
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
viru
neutral
activ
antisera
either
anim
covid
neutral
activ
rabbit
sera
evalu
pseudoviru
horizont
coordin
serum
dilut
vertic
coordin
percentag
neutral
b
neutral
titer
monkey
convalesc
patient
sera
examin
use
live
vertic
coordin
neutral
titer
ccbyncnd
intern
licens
certifi
peer
review
authorfund
made
avail
copyright
holder
preprint
version
post
april
http
doi
biorxiv
preprint
